FrancophonIA/ELRC3.0 huggingface dataset:
English: The volume of one vial ranges from 0.075 - 3.75 mL solution (corresponding to 3 - 150 GBq at activity reference time).
Estonian: Iga viaal sisaldab 0,075-3,75 ml lahust (vastab aktiivsusele vahemikus 3-150 GBq aktiivsuse referentsajal).
English: The presence of free Lutetium (177Lu) chloride in the body after an inadvertent administration of EndolucinBeta will lead to increased bone marrow toxicity and haematopoietic stem cell damage.
Estonian: Vaba luteetsium(177Lu)kloriidi esinemine organismis pärast EndolucinBeta tahtmatut manustamist suurendab luuüditoksilisust ja vereloome tüvirakkude kahjustumist.
English: Hormone release syndromes
Estonian: Hormoonvabanemise sündroomid
English: The complexing agent and other reagents should be added to the vial with Lutetium (177Lu) chloride.
Estonian: Kompleksi moodustaja ja teised reaktiivid tuleb lisada luteetsium(177Lu)kloriidi viaali.
English: EndolucinBeta 40 GBq/mL Lutetium (177Lu) chloride
Estonian: EndolucinBeta 40 GBq/ml Luteetsium(177Lu)kloriid
English: Radiolabelled somatostatin analogues are excreted by the kidney.
Estonian: Radiomärgisega somatostatiini analoogid erituvad neerude kaudu.
English: Medicines radiolabelled with EndolucinBeta will only be used in special controlled areas.
Estonian: EndolucinBetaga radiomärgistatud ravimeid tohib kasutada üksnes spetsiaalsel piiratud alal.
English: After neuroendocrine tumours are treated with Lutetium (177Lu), patients may experience symptoms associated with release of hormones from the tumour cells, known as a carcinoid crisis.
Estonian: Pärast neuroendokriinse kasvaja ravi luteetsiumiga (177Lu) võivad patsientidel tekkida kasvajarakkudest hormoonide vabanemisega seotud sümptomid, mida nimetatakse kartsinoidseks kriisiks.
English: Taking into account the PRAC Assessment Report on the PSUR(s) for Lutetium (177Lu) chloride, the scientific conclusions of the CHMP are as follows:
Estonian: Võttes arvesse ravimiohutuse riskihindamise komitee hindamisaruannet luteetsium(177Lu)kloriidi perioodilise ohutusaruande (perioodiliste ohutusaruannete) kohta, on inimravimite komitee teaduslikud järeldused järgmised.
English: The produced Ytterbium (177Yb) with a half-life of 1.9 h decays to Lutetium (177Lu).
Estonian: Tekkiv üterbium (177Yb) poolväärtusajaga 1,9 h laguneb luteetsiumiks (177Lu).
English: Please read the package leaflet of that medicine.
Estonian: Palun lugege asjaomase ravimi pakendi infolehte.
English: No interaction studies of Lutetium (177Lu) chloride with other medicinal products have been performed.
Estonian: Luteetsium(177Lu)kloriidi ja teiste ravimite koostoimeuuringuid ei ole tehtud.
English: Therefore, Lutetium metal-ion toxicity of EndolucinBeta (177Lu)-labelled medicinal products can be excluded.
Estonian: Seetõttu võib EndolucinBetaga (177Lu) märgistatud ravimpreparaatide luteetsiumi metalliioonide toksilisuse välistada.
English: Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects.
Estonian: Kokkupuudet ioniseeriva kiirgusega seostatakse vähkkasvajate ja pärilike häirete tekkeohuga.
English: The toxicity of non-radioactive Lutetium chloride has been studied in different mammalian species and using different administration routes.
Estonian: Mitteradioaktiivse luteetsiumkloriidi toksilisust on uuritud eri imetajatel ja eri manustamisviisidega.
English: Colourless type I glass 2 mL or 10 mL vial with a V-shaped and flat bottom, respectively, with a bromobutyl stopper, closed with an aluminium seal.
Estonian: Värvitu I tüüpi 2 ml või 10 ml V-kujulise või lameda põhjaga klaasviaal, mis on suletud bromobutüülkummist korgi ja alumiiniumist ümbrisega.
English: The PRAC therefore recommends that the Product Information should be updated accordingly.
Estonian: Ravimiohutuse riskihindamise komitee soovitav seetõttu ravimiteavet vastavat uuendada.
English: During peptide-receptor radionuclide therapy for neuroendocrine tumours, radiolabelled somatostatin analogues are excreted by the kidneys.
Estonian: Neuroendokriinsete kasvajate peptiidi-retseptorite ravi ajal väljutavad neerud radiomärgistatud somatostatiini analooge.
English: The vials are placed into a lead container for protective shielding and packed in a metallic can and an outer carton.
Estonian: Viaalid on kiirgust varjestavas pliikonteineris ning pakitud metallpurki ja kartongpakendisse.
English: EndolucinBeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients.
Estonian: EndolucinBeta on radiofarmatseutiline prekursor, mis ei ole ette nähtud vahetuks kasutamiseks patsientidel.
English: Heart Wall Kidneys
Estonian: Neerupealised Peaaju
English: There have been reports of carcinoid crisis and other syndromes associated with release of hormones from functional neuroendocrine tumours following Lutetium (177Lu) peptide receptor radionuclide therapy, which may be related to irradiation of tumour cells.
Estonian: Teavitatud on kartsinoidsest kriisist ja muudest sündroomidest, seoses hormoonide vabanemisega neuroendkokriinsest kasvajast pärast luteetsiumi (177Lu) peptiidi retsptori radionukliidravi, mis võib olla seotud kasvajarakkude kiiritamisega.
English: Blood and lymphatic system disorders: very common: Anaemia, thrombocytopenia, leukopenia and lymphopenia Endocrine disorders: not known: Carcinoid crisis
Estonian: Väga sage: aneemia, trombotsütopeenia, leukopeenia ja lümfopeenia Endokriinsüsteemi häired:
English: In a chromatographic process, the accumulated Lutetium (177Lu) is separated chemically from the original target material.
Estonian: Kromatograafilise protsessiga eraldatakse kogunenud luteetsium (177Lu) keemiliselt algupärasest sihtmaterjalist.
English: See section 4.
Estonian: Tabel 2.
English: The administration will depend on the type of the carrier medicine.
Estonian: Manustamine sõltub kanderavimi tüübist.
English: Administration of the medicine radiolabelled with EndolucinBeta and conduct of the procedure
Estonian: EndolucinBetaga radiomärgistatud ravimi manustamine ja protseduuri läbiviimine
English: Renal function as well as electrolyte balance should be assessed at baseline and during treatment.
Estonian: Enne ravi ja ravi ajal tuleb hinnata neerufunktsiooni ja elektrolüütide tasakaalu.
English: Myelodysplastic syndrome and acute myeloid leukaemia
Estonian: Müelodüsplastiline sündroom ja äge müeloidleukeemia
English: Radiation protection precautions in accordance with national regulations must therefore be taken.
Estonian: Sel põhjusel tuleb võtta riiklike eeskirjadega ettenähtud kiirguskaitsemeetmed.
English: Free non-bound Lutetium (177Lu) should be consequently minimised.
Estonian: Sel põhjusel tuleb minimeerida vaba seondumata luteetsium (177Lu) sisaldust.
English: In any case, the blood parameters of the patient have to be monitored and the appropriate actions immediately taken if there is evidence of radiotoxicity.
Estonian: Alati tuleb jälgida patsiendi verenäitajaid ja luuüdi kahjustusnähtude ilmnemisel võtta kohe asjakohased meetmed.
English: Only syringe needles (for example, non-metallic) with proven resistance to dilute acid should be used to minimise trace metal impurity levels.
Estonian: Metalliliste lisandite sisalduse minimeerimiseks tohib kasutada ainult happekindlaid süstlanõelu (nt mittemetallist).
English: What you need to know before the medicine radiolabelled with EndolucinBeta is used The medicine radiolabelled with EndolucinBeta must not be used
Estonian: Mida on vaja teada enne EndolucinBetaga radiomärgistatud ravimi kasutamist EndolucinBetaga radiomärgistatud ravimeid ei tohi kasutada:
English: If the integrity of this vial is compromised, the product should not be used.
Estonian: Kui viaal on kahjustunud, ei tohi preparaati kasutada.
English: It is presented as a clear and colourless solution in a colourless type I glass 2 mL or 10 mL vial with a V-shaped and flat bottom, respectively, with a bromobutyl stopper, closed with an aluminium seal.
Estonian: EndolucinBeta on läbipaistev ja värvitu lahus värvitus I tüüpi 2 ml või 10 ml klaasviaalis, millel on V-kujuline või lame põhi ning mis on suletud bromobutüülkummist korgi ja alumiiniumist ümbrisega.
English: Hydrochloric acid solution
Estonian: Vesinikkloriidhape, lahjendatud
English: Adequate quality control of the radiochemical purity of ready to use radiopharmaceuticals gained after radiolabelling with EndolucinBeta should be assured.
Estonian: Tagada tuleb EndolucinBetaga radiomärgistatud kasutuskõlblike radiofarmatseutikumide radiokeemilise puhtuse adekvaatne kvaliteedikontroll.
English: Other medicines and medicines radiolabelled with EndolucinBeta
Estonian: Muud ravimid ja EndolucinBetaga radiomärgistatud ravimid
English: - if you are allergic to Lutetium (177Lu) chloride or any of the other ingredients of this medicine
Estonian: - kui olete luteetsium(177Lu)kloriidi või selle ravimi mis tahes koostisosa(de) (loetletud lõigus 6)
English: Treatment with Lutetium (177Lu) may cause tumour lysis syndrome, due to the rapid breakdown of tumour cells.
Estonian: Ravi luteetsiumiga (177Lu) võib kutsuda kasvajarakkude kiire lagunemise tõttu esile tuumorilüüsi sündroomi.
English: Contact your nuclear medicine doctor if you have any questions.
Estonian: Küsimuste korral võtke palun ühendust oma nukleaarmeditsiini arstiga.
English: In all cases, the risk of the radiation is outweighed by the potential benefit of receiving the radiolabelled medicine.
Estonian: Igal juhul on radiomärgistatud ravimi manustamisest saadav võimalik kasu suurem kui kiirgusrisk.
English: Information on radiation dosimetry of each different medicinal product following administration of the radiolabelled preparation is available in the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Estonian: Radiomärgistatud preparaadi manustamise järgsed kiirgusdoosi andmed iga preparaadi kohta on esitatud radiomärgistatava ravimpreparaadi ravimi omaduste kokkuvõttes või pakendi infolehel.
English: EndolucinBeta is a radiopharmaceutical precursor, solution.
Estonian: EndolucinBeta on radiofarmatseutiline prekursor, lahus.
English: The quantity of EndolucinBeta required for radiolabelling and the quantity of Lutetium (177Lu)-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use.
Estonian: Radiomärgistuseks vajaliku EndolucinBeta ja seejärel manustatava luteetsiumiga (177Lu) märgistatud ravimpreparaadi kogus sõltub radiomärgistatud ravimpreparaadist ja selle kasutuseesmärgist.
English: How EndolucinBeta is stored
Estonian: Kuidas EndolucinBetat säilitada
English: How the medicine radiolabelled with EndolucinBeta is used
Estonian: Kuidas EndolucinBetaga radiomärgistatud ravimit kasutada
English: Adverse reactions are divided into groups according to the MedDRA convention frequencies: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000
Estonian: Kõrvaltoimed on rühmitatud vastavalt MedDRA esinemissageduste kategooriatele: väga sage (≥ 1/10),
English: It contains the active substance Lutetium (177Lu) chloride which gives off beta-radiation, allowing a localised radiation effect.
Estonian: EndolucinBeta sisaldab toimeainena luteetsium(177Lu)kloriidi, millest eraldub beetakiirgust, mis tekitab lokaalse kiirgusefekti.
English: EndolucinBeta 40 GBq/mL radiopharmaceutical precursor, solution Lutetium (177Lu) chloride
Estonian: EndolucinBeta 40 GBq/ml radiofarmatseutiline prekursor, lahus Luteetsium(177Lu)kloriid
English: Each 10 mL vial contains an activity ranging from 8 - 150 GBq, corresponding to 1.936 micrograms of Lutetium (177Lu), at ART.
Estonian: Igas 10 ml viaalis sisalduv ravimi aktiivsus on vahemikus 8-150 GBq, mis vastab 1,9-36 mikrogrammile luteetsiumile (177Lu) aktiivsuse referentsajal (ART).
English: The dosimetry table below is presented in order to evaluate the contribution of non-conjugated Lutetium (177Lu) to the radiation dose following the administration of a Lutetium (177Lu)-labelled medicinal product or resulting from an accidental intravenous injection of EndolucinBeta.
Estonian: Alljärgneva dosimeetriatabeli alusel saab hinnata konjugeerimata luteetsiumi (177Lu) osa kiirgusdoosis pärast luteetsiumiga (177Lu) märgistatud ravimpreparaadi manustamist või kui EndolucinBetat on tahtmatult veeni süstitud.
English: However, a post-exposure interval > 1 hour does not preclude the administration and effective action of chelator with reduced efficiency.Intravenous administration should not be protracted over more than 2 hours.
Estonian: Kui kokkupuutest on möödunud > 1 h, ei tähenda see, et kelaativa aine manustamine oleks välistatud ja toime vähem tõhus.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING METALLIC CAN AND OUTER CARTON
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED METALLPURK JA KARTONGPAKEND
English: If you have been given more medicine radiolabelled with EndolucinBeta than you should
Estonian: Kui teile manustatakse EndolucinBetaga radiomärgistatud ravimit rohkem kui ette nähtud
English: The toxicity of free Lutetium (177Lu) due to in-vivo release from the labelled biomolecule in the body during therapy could be reduced by post-administration of chelating agents.
Estonian: Ravi ajal märgistatud biomolekulist organismi vabanenud vaba luteetsiumi (177Lu) toksilisust in vivo saab vähendada kelaativate ainete järelmanustamisega.
English: Each 2 mL vial contains an activity ranging from 3 - 80 GBq, corresponding to 0.73 - 19 micrograms of Lutetium (177Lu), at ART.
Estonian: Igas 2 ml viaalis sisalduv ravimi aktiivsus on vahemikus 3-80 GBq, mis vastab 0,73-19 mikrogrammile luteetsiumile (177Lu) aktiivsuse referentsajal (ART).
English: For this reason it is mandatory to use protective high quality (latex/nitrile) gloves in any direct contact with the radiopharmaceutical (vial/syringe) and with the patient.
Estonian: (viaal/süstal) ja patsiendiga kvaliteetseid (lateks/nitriil) kaitsekindaid.
English: EndolucinBeta 40 GBq/mL radiopharmaceutical precursor, solution
Estonian: EndolucinBeta 40 GBq/ml radiofarmatseutiline prekursor, lahus
English: Excipient: Hydrochloric acid solution
Estonian: Abiaine: Vesinikkloriidhape, lahjendatud
English: - The active substance is Lutetium (177Lu) chloride.
Estonian: - Toimeaine on luteetsium(177Lu)kloriid.
English: Healthcare personnel are advised to limit the time of close contact with patients injected with Lutetium (177Lu)-labelled radiopharmaceuticals.
Estonian: Tervishoiutöötajatel soovitatakse võimalikult lühikest kokkupuuteaega patsientidega, kellele on süstitud luteetsiumiga (177Lu) märgistatud radiofarmatseutikume.
English: Red Marrow Osteogenic Cells Skin
Estonian: Osteogeensed rakud 2,1500 Nahk
English: It is recommended to add a binding agent such as DTPA prior to intravenous administration of Lutetium (177Lu)-labelled conjugates in order to form a complex with free Lutetium (177Lu), if present, leading to a rapid renal clearance of Lutetium (177Lu).
Estonian: Enne luteetsiumiga (177Lu) märgistatud konjugaatide intravenoosset manustamist on soovitatav lisada sideainet (nt DTPA), et siduda esinev vaba luteetsium (177Lu) kompleksi, mis eraldab luteetsiumi (177Lu) organimsist kiiresti neerude kaudu.
English: The radiation dose received by various organs following intravenous administration of a Lutetium (177Lu)-labelled medicinal product is dependent on the specific molecule being radiolabelled.
Estonian: Luteetsiumiga (177Lu) märgistatud ravimite intravenoosse manustamise järgne kiirgusdoos eri elundites sõltub konkreetsest radiomärgistatud molekulist.
English: Tumour lysis syndrome
Estonian: Tuumorilüüsi sündroom
English: 1 mL sterile solution contains 40 GBq Lutetium (177Lu) chloride on the activity reference time (corresponding to 10 micrograms of Lutetium (177Lu) as Lutetium (177Lu) chloride).
Estonian: 1 ml steriilset lahust sisaldab 40 GBq luteetsium(177Lu)kloriidi aktiivsuse referentsajal (vastab 10 mikrogrammile luteetsiumile (177Lu) luteetsium(177Lu)kloriidina).
English: Radiation nephropathy has been reported following peptide receptor radionuclide therapy for neuroendocrine tumours using other radioisotopes.
Estonian: Neuroendokriinsete kasvajate peptiidi retseptori radionukliidravi järgselt teiste radioisotoopidega on teatatud kiirituse põhjustatud nefropaatia juhtudest.
English: For more information, refer to the package leaflet of the particular medicinal product to be radiolabelled.
Estonian: Lisateave on asjaomase radiomärgistatava ravimi pakendi infolehel.
English: Liver
Estonian: Lihas
English: Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.
Estonian: Radiofarmatseutikume säilitatakse radioaktiivsete ainete säilitamise riiklike eeskirjade kohaselt.
English: Storage of radiopharmaceuticals should be in accordance with national regulation on radioactive materials.
Estonian: Radiofarmatseutikume tuleb säilitada vastavalt radioaktiivsete materjalide säilitamise riiklikele nõuetele.
English: Cases of hepatotoxicity have been reported in the post-marketing setting and in the literature in patients with liver metastases undergoing treatment with Lutetium (177Lu) peptide receptor radionuclide therapy for neuroendocrine tumours.
Estonian: Turustusjärgselt ning kirjanduses on teatatud hepatotoksilisuse juhtudest maksametastaasidega patsientidel, kes saavad luteetsiumi (177Lu) peptiidi retseptori radionukliidravi neuroendokriinse kasvaja tõttu.
English: EndolucinBeta should not be administered directly to the patient.
Estonian: EndolucinBetat ei tohi manustada vahetult patsiendile.
English: 1 mL of solution contains 40 GBq Lutetium (177Lu) chloride on activity reference time (ART), corresponding to 10 micrograms of Lutetium (177Lu) (as chloride).
Estonian: 1 ml lahust sisaldab 40 GBq luteetsium(177Lu)kloriidi aktiivsuse referentsajal (ART), mis vastab 10 mikrogrammile luteetsiumile (177Lu) (kloriidina).
English: Five cases of tumour lysis syndrome (TLS) were identified in the scientific literature in association with Lu-177 based radioligand therapy (RLT).
Estonian: Teaduskirjanduses tuvastati viis luteetsium(177Lu)kloriidi põhise radioligandravi kasutamisega seotud tuumorilüüsi sündroom (TLS) juhtu.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL (2 mL, 10 mL)
Estonian: VIAAL (2 ml, 10 ml)
English: It has to be used in combination with other medicines (carrier medicines).
Estonian: EndolucinBetat tuleb kasutada kombinatsioonis teiste ravimitega (kanderavimid).
English: EndolucinBeta is not intended for direct use in patients.
Estonian: EndolucinBeta ei ole ette nähtud vahetuks kasutamiseks patsientidel.
English: Such information will be supplied in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Estonian: See teave on esitatud radiomärgistatava preparaadi ravimi omaduste kokkuvõttes või pakendi infolehel.
English: Gamma 208.3662 * mean energies are listed for beta particles Lutetium (177Lu) decays by emission of beta radiation to stable Hafnium (177Hf).
Estonian: Gamma 208,3662 * Beetaosakeste kohta on esitatud keskmine energia.
English: Further information concerning the use of Lutetium (177Lu)-labelled medicinal products concerning fertility is specified in the Summary of Product Characteristics of the medicinal product to be radiolabelled.
Estonian: Luteetsiumiga (177Lu) märgistatud ravimite kasutamise lisateave seoses fertiilsusega on radiomärgistatava preparaadi ravimi omaduste kokkuvõttes.
English: EndolucinBeta has to be combined with a carrier medicine in a process called radiolabelling before administration.
Estonian: EndolucinBetat tuleb enne manustamist kombineerida kanderavimiga.
English: There have been reports of extravasation of Lutetium (177Lu) labelled ligands in the post-marketing setting.
Estonian: Turuletulekujärgsel kasutamisel on teatatud luteetsiumiga (177Lu) märgistatud ligandite ekstravasatsioonist.
English: It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride.
Estonian: Preparaati kasutatakse ainult spetsiaalselt luteetsium(177Lu)kloriidiga radiomärgistamiseks välja töötatud ja vastava loa saanud kandemolekulide radiomärgistamiseks.
English: EndolucinBeta is not to be administered directly to patients.
Estonian: EndolucinBetat ei tohi manustada vahetult patsientidele.
English: EndolucinBeta is a type of product called a radiopharmaceutical precursor.
Estonian: EndolucinBeta on radiofarmatseutiline prekursor.
English: For information concerning special warnings and special precautions for use of Lutetium (177Lu)labelled medicinal products refer also to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Estonian: Luteetsiumiga (177Lu) märgistatud ravimpreparaatide kasutamise erihoiatuste ja ettevaatusabinõude teavet lugege ka radiomärgistatava ravimpreparaadi ravimi omaduste kokkuvõttest või pakendi infolehelt.
English: Dry mouth has been reported among patients with metastatic castration resistant prostate cancer receiving PSMA-targeted Lutetium (177Lu)-labelled radioligands and has been transient.
Estonian: Kastratsiooni suhtes resistentse metastaatilise eesnäärmevähiga patsientidel, kes said eesnäärmespetsiifilisele membraani antigeenile (PSMA) suunatud luteetsiumiga (177Lu) märgistatud radioligande on teatatud mööduvast suukuivusest.
English: Lutetium (177Lu) chloride This medicine is subject to additional monitoring.
Estonian: Luteetsium(177Lu)kloriid Käesoleva ravimi suhtes kohaldatakse täiendavat järelevalvet, mis võimaldab kiiresti tuvastada uut ohutusteavet.
English: 1 mL of solution contains 40 GBq of Lutetium (177Lu) chloride at activity reference time (ART).
Estonian: 1 ml lahust sisaldab 40 GBq luteetsium(177Lu)kloriidi aktiivsuse referentsajal (ART).
English: EndolucinBeta must not be used after the expiry date and time which is stated on the label after EXP. EndolucinBeta will be stored in the original package that provides protection from radiation.
Estonian: EndolucinBetat säilitatakse originaalpakendis, mis tagab kaitse radioaktiivsuse eest.
English: Side effects reported among patients treated for neuroendocrine tumors:
Estonian: Neuroendokriinsete kasvajate ravi saanud patsientidel teatatud kõrvaltoimed
English: …GBq/vial at ART
Estonian: AKTIIVSUS: … GBq/viaal aktiivsuse referentsajal (ART)
English: Storage should be in accordance with local regulations for radioactive substances.
Estonian: Säilitada vastavalt radioaktiivsete materjalide säilitamise kohalikele eeskirjadele.
English: Dry mouth has been reported among patients with prostate cancer receiving treatment with Lutetium (177Lu) and has been temporary.
Estonian: Eesnäärmevähiga patsientidel, keda raviti luteetsiumiga (177Lu) on teatatud suukuivusest, mis on olnud mööduv.
English: Adverse reactions following the administration of a Lutetium (177Lu)-labelled medicinal product prepared by radiolabelling with EndolucinBeta will be dependent on the specific medicinal product being used.
Estonian: Kõrvaltoimed, mis võivad tekkida pärast EndolucinBeta kasutamisel luteetsiumiga (177Lu) märgistatud ravimpreparaatide manustamist, sõltuvad konkreetsest ravimpreparaadist.
English: It will be the smallest quantity necessary to achieve the appropriate outcome, depending on the medicine you take with EndolucinBeta and what it is used for.
Estonian: Sõltuvalt EndolucinBetaga koos kasutatavast ravimist ja selle kasutamise eesmärgist kasutatakse väikseimat võimalikku annust, mis tagab soovitud tulemuse.
English: Please refer to the package leaflet of the medicine that is to be radiolabelled with EndolucinBeta.
Estonian: Palun tutvuge ka EndolucinBetaga radiomärgistatava ravimi pakendi infolehega.
English: Ovaries
Estonian: Munasarjad
English: Breasts
Estonian: Rasedus
English: EndolucinBeta is intended for in vitro radiolabelling of medicinal products which are subsequently administered by the approved route.
Estonian: EndolucinBeta on ette nähtud ravimite radiomärgistamiseks in vitro.
English: Muscle
Estonian: Kilpnääre
English: Table 1: Lutetium (177Lu) principle radiation emission data
Estonian: Luteetsiumi (177Lu) peamised kiirgusomadused